@article{c5ae611e87f840fcbfb36a796b41c301,
title = "Use of the CDR{\textregistered} plus NACC FTLD in mild FTLD: Data from the ARTFL/LEFFTDS consortium",
abstract = "Introduction: Behavior/Comportment/Personality (BEHAV) and Language (LANG) domains were added to the Clinical Dementia Rating (CDR{\textregistered}) for improving evaluation of patients with frontotemporal lobar degeneration (FTLD) (CDR{\textregistered} plus NACC FTLD). Methods: We analyzed the CDR{\textregistered} plus NACC FTLD among participants from the baseline visit of the Advancing Research and Treatment for Frontotemporal Lobar Degeneration/Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects Consortium. Results: The CDR{\textregistered} plus NACC FTLD was able to detect early symptoms in the mildly impaired participants who were rated as CDR{\textregistered} sum of boxes (CDR{\textregistered}-SB) = 0. The CDR{\textregistered}-SB was not sensitive, particularly in participants with mild nonfluent/agrammatic primary progressive aphasia. Participants with familial and sporadic behavioral variant FTD exhibited similar CDR{\textregistered} plus NACC FTLD profiles except that language impairment was more frequent in participants with mild sporadic behavioral variant FTD. Adding the BEHAV and/or LANG domains to the CDR{\textregistered}-SB significantly enhanced discriminatory power in differentiating among the FTLD spectrum disorders. Discussion: The BEHAV and LANG domains enable the CDR{\textregistered} plus NACC FTLD to capture early symptomatology of FTLD.",
keywords = "Behavior, CDR{\textregistered}, Comportment and personality, Frontotemporal dementia, Frontotemporal lobar degeneration, Language, NACC FTLD Module, Primary progressive aphasia",
author = "{on behalf of the ARTFL/LEFFTDS consortium} and Toji Miyagawa and Danielle Brushaber and Jeremy Syrjanen and Walter Kremers and Julie Fields and Forsberg, {Leah K.} and Heuer, {Hilary W.} and David Knopman and John Kornak and Adam Boxer and Howie Rosen and Bradley Boeve",
note = "Funding Information: Funding: This work is supported by the National Institutes of Health (grants U01 AG045390 , U54 NS092089 , U24 AG021886 , and U01 AG016976 ). Funding Information: Listed as additional members of the A/L consortium: B.A. receives research support from CDC and NIH ; J.B. has nothing to disclose; Y.B. has nothing to disclose; P.B. is employed by the Rainwater Charitable Foundation; S.D. is a staff at the Association for Frontotemporal Degeneration and a member of the National Institute for Neurological Disorders and Stroke Advisory Council. C.C. has nothing to disclose; G.C. receives research support from NIH; R.D. has nothing to disclose; C.D. has nothing to disclose; B.D. receives research support from NIH . K.D.-R. has nothing to disclose; J.F. has nothing to disclose; K.F. receives research support from NIH; T.F. receives research support from NIH ; A.F. has nothing to disclose; J.F. has nothing to disclose; R.G. receives research support from NIH; D.G. has nothing to disclose; B.G. has nothing to disclose; N.G. has participated or is currently participating in clinical trials of antidementia drugs sponsored by the following companies: Bristol-Myers Squibb , Eli Lilly / Avid Radiopharmaceuticals , Janssen Immunotherapy , Novartis , Pfizer , Wyeth , SNIFF (The Study of Nasal Insulin to Fight Forgetfulness), and A4 (The Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease) trial. She receives research support from Tau Consortium and Association for Frontotemporal Dementia and is funded by the NIH . J.S.G. is serving as a consultant to the Novartis Alzheimer's Prevention Advisory Board. She receives research support from NIH , HDSA , New York State Department of Health (RFA # 1510130358 ). J.G.-R. receives research support from the NIH . N.G.-R. receives royalties from UpToDate and has participated in multicenter therapy studies by sponsored by Biogen , TauRx , AbbVie , Novartis , and Lilly . He receives research support from NIH . I.G. has nothing to disclose. M.G. receives grant support from NIH , Avid, and Piramal; participates in clinical trials sponsored by Biogen , TauRx, and Alector; serves as a consultant to Bracco and UCB; and serves on the Editorial Board of Neurology. D.H. has nothing to disclose. R.H. has served as an investigator for clinical trials sponsored by AstraZeneca , Eli Lilly , and Roche / Genentech . He receives research support from Canadian Institutes of Health Research and the Alzheimer Society of British Columbia . E.H. receives research support from NIH; D.I. receives support from NIH , BrightFocus Foundation , and Penn Institute on Aging . D.J. receives research support from NIH and the Minnesota Partnership for Biotechnology and Medical Genomics. L.J. has nothing to disclose. K.K. served on the Data Safety Monitoring Board for Takeda Global Research & Development Center, Inc. and data monitoring boards of Pfizer and Janssen Alzheimer Immunotherapy and received research support from the Avid Radiopharmaceuticals , Eli Lilly , the Alzheimer's Drug Discovery Foundation , and NIH . A.K. has nothing to disclose. D.K. has nothing to disclose. D.K. has served on an Advisory Board for AbbVie and as site principal investigator for studies funded by Roche / Genentech , AbbVie , Avid , Novartis , Eisai , Eli Lilly, and UCSF . R.K. has nothing to disclose. J.K. has nothing to disclose. W.K. receives research support from NIH . I.L. receives research support from NIH , Parkinson Study Group , Parkinson Foundation , Michael J. Fox Foundation , AVID Pharmaceuticals , C2N Diagnostics/ AbbVie , and Bristol-Myers Squibb . She was a member of the Biogen and Bristol-Myers Squibb Advisory Boards and Biotie/Parkinson Study Group Medical Advisory Board and was a consultant for Toyama Pharmaceuticals. She receives salary from the University of California San Diego and as an editor in Frontiers in Neurology. D.L. receives research support from NIH . C.L. receives honoraria for editorial work from Elsevier, Inc. I.M. receives research funding from the Canadian Institutes of Health Research . M.M. has nothing to disclose. M.M. has nothing to disclose. S.M. has served as an investigator for clinical trials sponsored by AbbVie , Allon Therapeutics , Biogen , Bristol-Myers Squibb , C2N Diagnostics , Eisai Inc. , Eli Lilly and Co. , Genentech , Janssen Pharmaceuticals , Medivation , Merck , Navidea Biopharmaceuticals , Novartis , Pfizer , and TauRx Therapeutics . He receives research support from NIH . E.M. has nothing to disclose. M.F.M. receives research support from NIH . B.M. receives research support from NIH . N.M. has nothing to disclose. C.O. receives research funding from the NIH , the CIHR , and Biogen , Inc. He is also supported by the Jane Tanger Black Fund for Young-Onset Dementias , the Nancy H. Hall Fund for Geriatric Psychiatry, and the gift from Joseph Trovato. J.P. has nothing to disclose. A.P. has nothing to disclose. R.P. is employed by The Bluefield Project. L.P. receives research support from NIH . M.P. receives research support from NIH . R.R. receives research funding from NIH and the Bluefield Project to Cure Frontotemporal Dementia. E.M.R. has nothing to disclose. K.R. receives research support from NIH . K.R. receives research support from NIH . E.D.R. receives research support from NIH , Bluefield Project to Cure Frontotemporal Dementia, Alzheimer's Association , BrightFocus Foundation , Biogen , and Alector and owns intellectual property related to tau. E.R. has nothing to disclose. P.S. has nothing to disclose. L.S. receives research support from NIH . M.C.T. has nothing to disclose. N.T. is employed by the Association for Frontotemporal Degeneration. J.T. has nothing to disclose. A.T. receives research support from the NIH and the Alzheimer's Association . J.Q.T. may accrue revenue in the future on patents submitted by the University of Pennsylvania wherein he is the coinventor and he received revenue from the sale of Avid to Eli Lily as a coinventor on Aβ amyloid imaging–related patents submitted by the University of Pennsylvania. He receives research support from the NIH and several nonprofit benefits. P.W. has nothing to disclose. S.W. receives research support from the NIH . B.W. receives research support from the NIH . Z.W. is supported by the NIH , Mayo Clinic Center for Regenerative Medicine, the gift from Carl Edward Bolch, Jr. and Susan Bass Bolch, The Sol Goldman Charitable Trust, and Donald G. and Jodi P. Heeringa. He has also received grant funding support from Allergan, Inc . (educational grant) and Abbvie (medication trials).",
year = "2020",
month = jan,
day = "1",
doi = "10.1016/j.jalz.2019.05.013",
language = "English (US)",
volume = "16",
pages = "79--90",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "1",
}